FIELD: chemistry.
SUBSTANCE: invention relates to substituted piperidine compounds having orexin receptor type 2 activating activity. Disclosed is a compound selected from the group consisting of (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide of formula (I), (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutanamide of formula (II), (R)-2-((1R, 3S, 5S)-3-((3S, 4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropylacetamide of formula (III) and (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S,4S) -1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide of formula (IV), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions, therapeutic agents, methods of treating narcolepsy and cataplexy and use of compounds of formula (I) for preparing pharmaceutical compositions are also provided.
EFFECT: disclosed compound has type 2 orexin receptor activating activity and can be used as a therapeutic agent for treating narcolepsy and cataplexy.
16 cl, 3 dwg, 3 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZABICYCLIC AND DIAZEPINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS | 2018 |
|
RU2795521C2 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 2022 |
|
RU2803084C1 |
| SPIRO-FUSED PIPERIDINE DERIVATIVES FOR APPLICATION AS INHIBITORS OF EXTERNAL MEDULLAR LAYER POTASSIUM CHANNEL | 2013 |
|
RU2642066C2 |
| AMINOPYRIDINE DERIVATIVES AND APPLICATION THEREOF AS SELECTIVE ALK-2 INHIBITORS | 2017 |
|
RU2777979C2 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 2017 |
|
RU2747318C2 |
| DIPEPTIDYL PEPTIDASE-IV INHIBITORS | 2010 |
|
RU2574410C2 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ALK-2 SELECTIVE INHIBITORS | 2023 |
|
RU2826177C1 |
| MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS USING THEM AND WAYS OF USE THEREOF | 2020 |
|
RU2825271C2 |
| OXADIAZOLES AS MUSCARINIC RECEPTOR AGONISTS M AND/OR M | 2019 |
|
RU2817018C2 |
| C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
